IMA Overview

ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

Wall Street analysts forecast IMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMA is16.00 USD with a low forecast of 2.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

ImageneBio Inc revenue for the last quarter amounts to 0.00 USD, decreased

ImageneBio Inc. EPS for the last quarter amounts to -3.01 USD, increased 18.50

ImageneBio Inc (IMA) has 10 emplpoyees as of March 11 2026.

Today IMA has the market capitalization of 67.87M USD.